

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Application Number	10/062,467
				Filing Date	February 5, 2002
				First Named Inventor	Andrew C. Hiatt
				Group Art Unit	1651
				Examiner Name	
Sheet	1	of	5	Attorney Docket Number	068904-0204

[illegible][illegible]

Examiner Signature	 24. 	Date Considered	7/26/04
-----------------------	---	--------------------	---------

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/062,467
		Filing Date	February 5, 2002
		First Named Inventor	Andrew C. Hiatt
		Group Art Unit	1651
		Examiner Name	
(use as many sheets as necessary)		Attorney Docket Number	068904-0204
Sheet	2	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
am	A10	Allen, et al., "An immunoperoxidase study of epithelial marker antigens in ulcerative colitis with dysplasia and carcinoma." <i>J. Clin. Pathol.</i> , 38:18-29 (1985)	
am	A11	Arnold, et al., "Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer." <i>Surgery</i> , 112:624-631 (1992)	
am	A12	Ball, et al., "A polarized human endometrial cell line that binds and transports polymeric IgA." <i>In Vitro Cell Biol.</i> , 31:96 (1995)	
am	A13	Carayannopoulos, et al., "Localization of the Binding Site for the Monocyte Immunoglobulin (Ig) A-Fc Receptor (CD89) to the Domain Boundary Between Cα2 and Cα3 in Human IgA1." <i>J. Exp. Med.</i> , 183:1579-1586 (1996)	
am	A14	Church and Gilbert, "Genomic sequencing." <i>Proc. Natl. Acad. Sci. USA</i> , 81:1991-1995 (1984)	
am	A15	Creighton, Thomas E., <i>Proteins - Structures and Molecular Principles</i> , (New York: W.H. Freeman and Co.) pp. 2, 86-87.	
am	A16	Foll, et al., "Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice." <i>Cancer Res.</i> , 54:2643-2450 (1994)	
am	A17	Hughes, et al., "The amino acid sequence of rabbit J chain in secretory immunoglobulin A." <i>Biochem. J.</i> , 271:641-647 (1990)	
am	A18	Janknecht and Nordheim, "Affinity purification of histidine-tagged proteins transiently produced in HeLa cells." <i>Gene</i> , 121:321-324 (1992)	
am	A19	Kimball, John W., <i>Introduction to Immunology</i> (New York: Macmillan) pages 264-265, 1983.	

Examiner Signature		Date Considered	7/26/02
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the

amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Applicati n Number Filing Dat First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/062,467 February 5, 2002 Andrew C. Hiatt 1651 068904-0204
Sheet	3	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
am	A20	Lemaitre-Coelho, et al., "In vivo experiments involving secretory component in the rat hepatic transfer of polymeric IgA from blood into bile." <i>Immunology</i> , <u>43</u> :261 (1981).	
am	A21	Matsuuchi, et al., "Immunoglobulin J chain gene from the mouse." <i>Proc. Natl. Acad. Sci. USA</i> , <u>83</u> :456-460 (1986).	
am	A22	Max and Korsmeyer, "Human J chain gene." <i>J. Exp. Med.</i> , <u>161</u> :832-849 (1985).	
am	A23	Merrifield, R.B., "Solid phase peptide synthesis: The synthesis of a Tetrapeptide." <i>J. Am. Chem. Soc.</i> , <u>85</u> :2149-2146 (1963).	
am	A24	Mikoryak, et al., "J chain in <i>Rana catesbeiana</i> high molecular weight Ig." <i>J. Immunol.</i> , <u>140</u> :4279-4285 (1988).	
am	A25	Morton, et al., "Purification and Characterization of Chimeric Human IgA1 and IgA2 Expressed in COS and Chinese Hamster Ovary Cells," <i>The Journal of Immunology</i> , <u>151</u> (9):4743-4752 (1993).	
am	A26	Pelegrin, et al., "Antibody-Fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice." <i>Cancer</i> , <u>67</u> :2529-2535 (1994).	

Examiner Signature		Date Considered	7/26/04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/062,467
		Filing Date	February 5, 2002
		First Named Inventor	Andrew C. Hiatt
		Group Art Unit	1651
		Examiner Name	
Sheet	4	of	5
		Attorney Docket Number	068904-0204

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
am	A27	Piskurich, et al., "Molecular cloning of the mouse polymeric Ig receptor: Functional regions of the molecule are conserved among five mammalian species." <i>J. Immunol.</i> , <u>154</u> :1735-1747 (1995)	
am	A28	Suemori, et al., "Identification and characterization of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein family." <i>Proc. Natl. Acad. Sci.</i> , <u>88</u> :11017-11021 (1991).	
am	A29	Takahashi, et al., "The joining (J) chain is present in invertebrates that do not express immunoglobulins." <i>Proc. Natl. Acad. Sci. USA</i> , <u>93</u> :1886-1891 (1996).	
am	A30	Underdown, et al., "Isolation of human secretory component by affinity chromatography." <i>Immunochemistry</i> , <u>14</u> :111-120 (1977).	
am	A31	Verma & Somia, "Gene Therapy – promises, problems, and prospects." <i>Nature</i> , <u>389</u> :239-242 (1997).	
am	A32	Wagner, et al., "Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes." <i>Science</i> , <u>270</u> :1797-1800 (1995).	
am	A33	Weissleder, et al., "Quantitation of slow drug release from an implantable and degradable gentamicin conjugate by in Vivo magnetic resonance imaging." <i>Antimicrobial Agents and Chemotherapy</i> , <u>39</u> (4):839-845 (1995).	

Examiner Signature		Date Considered	7/24/02
--------------------	--	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/062,467
		Filing Date	February 5, 2002
		First Named Inventor	Andrew C. Hiatt
		Group Art Unit	1651
		Examiner Name	
(use as many sheets as necessary)		Attorney Docket Number	068904-0204
Sheet	5	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A34	Wells, J. A., "Additivity of Mutational Effects in Proteins," <i>Biochemistry</i> , 29(37):8509-8517 (1990).	

Examiner Signature	 	Date Considered	2/24/02
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 310098.402	APPLICATION NO. 08/782,480
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Andrew C. Hiatt et al.	
		FILING DATE January 10, 1997	GROUP ART UNIT

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
AB						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


AC	Ferkol et al., "Gene Transfer into Respiratory Epithelial Cells by Targeting the Polymeric Immunoglobulin Receptor," <i>J. Clin. Invest.</i> 92: 2394-2400, 1993.
AD	Terskikh et al., "Dimeric Recombinant IgA Directed Against Carcino-Embryonic Antigen, A Novel Tool For Carcinoma Localization," <i>Molecular Immunology</i> 31(17): 1313-1319, 1994.
AE	Hendrickson et al., "Altered Hepatic Transport of Immunoglobulin A in Mice Lacking the J Chain," <i>J. Exp. Med.</i> 182: 1905-1911, 1995.
AF	Max and Korsmeyer, "Human J Chain Gene. Structure and Expression in B Lymphoid Cells," <i>Journal of Experimental Medicine</i> 161: 832-849, 1985.
AG	Frutiger et al., "Disulfide Bond Assignment in Human J Chain and Its Covalent Pairing with Immunoglobulin M," <i>Biochemistry</i> 31: 12643-12647, 1992.
AH	Kulseth and Rogne, "Cloning and Characterization of the Bovine Immunoglobulin J Chain cDNA and Its Promoter Region," <i>DNA and Cell Biology</i> 13(1): 37-42, 1994.
AI	Rifai and Mannik, "Clearance Kinetics and Fate of Mouse IgA Immune Complexes Prepared with Monomeric or Dimeric IgA," <i>Journal of Immunology</i> 130(4): 1826-1832, 1983.
AJ	Burns et al., "Protective Effect of Rotavirus VP6-Specific IgA Monoclonal Antibodies That Lack Neutralizing Activity," <i>Science</i> 272: 104-107, 1996.
AK	Mazanec et al., "Intracellular Neutralization of Influenza Virus by Immunoglobulin A Anti-Hemagglutinin Monoclonal Antibodies," <i>Journal of Virology</i> 69(2): 1339-1343, 1995.
AL	Kaetzel et al., "The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: A local defense function for IgA," <i>Proc. Natl. Acad. Sci.</i> 88: 8796-8800, 1991.

EXAMINER 	DATE CONSIDERED 12/26/04
---	-----------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 310098.402		APPLICATION NO. 08/782,480	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Andrew C. Hiatt et al.		GROUP ART UNIT	
				FILING DATE January 10, 1997			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>aw</i>	BC	Kaetzel et al., "Epithelial Transcytosis of Monomeric IgA and IgG Cross-linked Through Antigen to Polymeric IgA. A Role for Monomeric Antibodies in the Mucosal Immune System," <i>Journal of Immunology</i> 152: 72-76, 1994.					
<i>aw</i>	BD	Sheldrake et al., "Selective Transport of Serum-Derived IgA Into Mucosal Secretions," <i>Journal of Immunology</i> 132(1): 363-368, 1984.					
<i>aw</i>	BE	Mestecky et al., "The Role of the Liver in Catabolism of Mouse and Human IgA," <i>Immunological Investigations</i> 18(1-4): 313-324, 1989.					
<i>aw</i>	BF	Youngman et al., "Inhibition of IFN- γ Activity in Supernatants from Stimulated Human Intestinal Mononuclear Cells Prevents Up-Regulation of the Polymeric Ig Receptor in an Intestinal Epithelial Cell Line," <i>Journal of Immunology</i> 153: 675-681, 1994.					
<i>aw</i>	BG	Rifai et al., "Clearance Kinetics and Fate of Macromolecular IgA in Patients with IgA Nephropathy," <i>Laboratory Investigation</i> 61(4): 381-388, 1989.					
<i>aw</i>	BH	Emancipator and Lamm, "IgA Nephropathy: Overproduction of Decreased Clearance of Immune Complexes?" <i>Laboratory Investigation</i> 61(4): 365-367, 1989.					
<i>aw</i>	BI	Nagura et al., "Translocation of Dimeric IgA Through Neoplastic Colon Cells <i>In Vitro</i> ," <i>Journal of Immunology</i> 123(5): 2359-2368, 1979.					
<i>aw</i>	BJ	Mannik and Arend, "Fate of Preformed Immune Complexes in Rabbits and Rhesus Monkeys," <i>Journal of Experimental Medicine</i> 134(3 pt. 2): 19s-31s, 1971.					
	BK						
	BL						
EXAMINER <i>[Signature]</i>				DATE CONSIDERED <i>7/26/09</i>			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP-609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

RECEIVED
08/27/2009

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 310098.402		APPLICATION NO. 08/782,480	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Andrew C. Hiatt et al.			
				FILING DATE January 10, 1997		GROUP ART UNIT 1651	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	AH						
	AI						
	AJ						
	AK						
	AL						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
an	AM	Henneberg et al., "Antibrain Antibodies in Alcoholic Patients," <i>Alcohol & Alcoholism</i> 28(2): 181-187, 1993.					
an	AN	Hammond, "Ultrastructural Characteristics of Surface IgM Reactive Malignant Lymphoid Cells," <i>Experimental Research</i> 59: 359-370, 1970.					
an	AO	Valnes and Brandtzaeg, "Comparison of Paired Immunofluorescence and Paired Immunoenzyme Staining Methods Based on Primary Antisera from the Same Species," <i>The Journal of Histochemistry and Cytochemistry</i> 30(6): 518-524, 1982.					
an	AP	Brown and Koshland, "Evidence for a long-range conformational change induced by antigen binding to IgM antibody," <i>Proc. Natl. Acad. Sci. USA</i> 74(12): 5682-5686, 1977.					
an	AQ	Brandtzaeg and Baklien, "Immunohistochemical studies of the immunoglobulin-producing cell systems of the human intestinal mucosa," <i>Acta histochemica, Suppl.</i> 21: 105-119, 1980.					
EXAMINER 				DATE CONSIDERED 7/26/04			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 310098.402		APPLICATION NO. 08/782,480	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Andrew C. Hiatt et al.		FILING DATE January 10, 1997	
				GROUP ART UNIT 1651			

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
AA	4,837,167	06/06/89	Schoemaker et al.	436	513		
AB	5,240,833	08/31/93	Nudelman et al.	435	70.21		
AC	5,484,707	01/16/96	Goldblum and Rajaraman	435	7.92		
AD	5,512,443	04/30/96	Schlom et al.	435	7.23		
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
			YES	NO	
AL	WO 98/30592	07/16/98 PCT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
AM					
AN					
AO					
AP					

OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
	AQ	Tamer et al., "Comparative Studies of Transcytosis and Assembly of Secretory IgA in Madin-Darby Canine Kidney Cells Expressing Human Polymeric Ig Receptor," <i>The Journal of Immunology</i> 155: 707-714, 1995.
	AR	
	AS	

EXAMINER 	DATE CONSIDERED 8/24/04
--------------	----------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 310098.402	APPLICATION NO. 08/782,480
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Andrew C. Hiatt et al.	
				FILING DATE January 10, 1997	GROUP ART UNIT 1651

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
			YES	NO	
AL JP 58134032	08/10/83	Japan (Abstract only)			
AM					
AN					
AO					
AP					

OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
AR		
AS		
AT		

EXAMINER 	DATE CONSIDERED 9/26/04
--------------	----------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).